Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis

C. L. M. Sudlow, Carl Edward Counsell

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The government plans to make interferon beta and glatiramer available to patients with multiple sclerosis through a risk sharing scheme, despite lack of evidence of cost effectiveness. Sudlow and colleagues argue that the money would be better spent on independent research.

Original languageEnglish
Pages (from-to)388-392
Number of pages4
JournalBritish Medical Journal
Volume326
DOIs
Publication statusPublished - 2003

Keywords

  • RANDOMIZED CONTROLLED-TRIAL
  • SECONDARY PROGRESSIVE MS
  • PLACEBO-CONTROLLED TRIAL
  • DOUBLE-BLIND
  • INTERFERON BETA-1B
  • GLATIRAMER ACETATE
  • NATURAL-HISTORY
  • CLINICAL-TRIALS
  • FINAL REPORT
  • RELAPSE RATE

Cite this